APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 4, 2018

Primary Completion Date

October 15, 2021

Study Completion Date

October 15, 2021

Conditions

Chronic Hepatitis B

Interventions

DRUG

APG-1387 for Injection

Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .

Trial Locations (2)

Nanfang Hospital of Southern Medical University, Guangzhou

Guangzhou Eighth People's Hospital, Guangzhou